PubRank

Serena Spudich

Author PubWeight™ 38.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010 3.46
2 Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012 2.37
3 Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010 1.99
4 Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007 1.92
5 Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol 2009 1.70
6 Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009 1.66
7 Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012 1.60
8 Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008 1.56
9 Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008 1.47
10 Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008 1.46
11 HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog 2011 1.45
12 Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 2013 1.42
13 Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 2009 1.32
14 Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One 2012 1.25
15 Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol 2006 1.24
16 Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009 1.08
17 An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis 2013 1.03
18 Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep 2015 1.03
19 Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol 2013 0.98
20 Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 2013 0.95
21 Cerebral white matter integrity during primary HIV infection. AIDS 2015 0.85
22 Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 2008 0.85
23 CNS reservoirs for HIV: implications for eradication. J Virus Erad 2015 0.83
24 Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation. J Acquir Immune Defic Syndr 2014 0.80
25 Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy. J Acquir Immune Defic Syndr 2015 0.80
26 Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics. Curr HIV/AIDS Rep 2014 0.79
27 Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. AIDS 2013 0.79
28 Longitudinal characterization of depression and mood states beginning in primary HIV infection. AIDS Behav 2014 0.78
29 Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. AIDS 2016 0.77
30 High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. J Acquir Immune Defic Syndr 2017 0.75